Successful treatment by thalidomide therapy of intestinal Behçet's disease associated with trisomy 8 myelodysplastic syndrome

Rheumatology (Oxford). 2021 Jun 18;60(6):e200-e202. doi: 10.1093/rheumatology/keaa848.

Authors

Affiliations

¹ Department of Gastroenterology, Southwest Hospital, Cholestatic Liver Diseases Center (CLDC), Army Medical, Chongqing, China.
² Institute of Burn Research, Chongqing, China.
³ Center for Hematology, Southwest Hospital, Army Medical University, Chongqing, China.

PMID: 33331901
DOI: 10.1093/rheumatology/keaa848

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Behcet Syndrome / blood
Behcet Syndrome / drug therapy*
Behcet Syndrome / genetics
Chromosomes, Human, Pair 8
Female
Humans
Immunosuppressive Agents / therapeutic use*
Intestinal Diseases / blood
Intestinal Diseases / drug therapy*
Intestinal Diseases / genetics
Middle Aged
Myelodysplastic Syndromes / complications
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / genetics*
Oral Ulcer / drug therapy
Thalidomide / therapeutic use*
Trisomy*

Substances

Immunosuppressive Agents
Thalidomide

Supplementary concepts

Chromosome 8, trisomy